Novartis-Amgen’s Aimovig Poised for India Debut
Executive Summary
Novartis is planning to launch Aimovig in India after the migraine therapy was endorsed by an expert panel, but all eyes will be on pricing and how the company’s recent dispute with partner Amgen plays out.
You may also be interested in...
Novartis India's New Chief Has A Full Plate
Ex-AstraZeneca executive Sanjay Murdeshwar will lead Novartis in India. The incoming head faces multiple challenges including balancing profitable growth and access in a largely self-pay market.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.